• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

18-64 岁有大型雇主赞助保险的员工中 2 型糖尿病导致的生产力损失和医疗费用。

Productivity Loss and Medical Costs Associated With Type 2 Diabetes Among Employees Aged 18-64 Years With Large Employer-Sponsored Insurance.

出版信息

Diabetes Care. 2022 Nov 1;45(11):2553-2560. doi: 10.2337/dc22-0445.

DOI:10.2337/dc22-0445
PMID:36048852
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9633402/
Abstract

OBJECTIVE

To estimate productivity losses and costs and medical costs due to type 2 diabetes (T2D) among employees aged 18-64 years.

RESEARCH DESIGN AND METHODS

Using 2018-2019 MarketScan databases, we identified employees with T2D or no diabetes among those with records on workplace absences, short-term disability (STD), and long-term disability (LTD). We estimated per capita mean annual time loss attributable to T2D and its associated costs, calculated by multiplying time loss by average hourly wage. We estimated direct medical costs of T2D in total and by service type (inpatient, outpatient, and prescription drugs). We used two-part models (productivity losses and costs and inpatient and drug costs) and generalized linear models (total and outpatient costs) for overall and subgroup analyses by age and sex. All costs were in 2019 U.S. dollars.

RESULTS

Employees with T2D had 4.2 excess days lost (20.8 vs. 20.3 absences, 6.4 vs. 3.3 STD days, and 1.0 vs. 0.4 LTD days) than those without diabetes. Productivity costs were 13.3% ($680) higher and medical costs were double (total $11,354 vs. $5,101; outpatient $4,558 vs. $2,687, inpatient $3,085 vs. $1,349, prescription drugs $4,182 vs. $1,189) for employees with T2D. Employees aged 18-34 years had higher STD days and outpatient costs. Women had more absences and STD days and higher outpatient costs than men.

CONCLUSIONS

T2D contributes nearly $7,000 higher annual per capita costs, mostly due to excess medical costs. Our estimates may assist employers to assess potential financial gains from efforts to help workers prevent or better manage T2D.

摘要

目的

估计 18-64 岁员工中 2 型糖尿病(T2D)导致的生产力损失和成本以及医疗费用。

研究设计和方法

使用 2018-2019 年 MarketScan 数据库,我们在有工作场所缺勤、短期残疾 (STD) 和长期残疾 (LTD) 记录的员工中,确定了患有 T2D 或无糖尿病的员工。我们估计了归因于 T2D 的人均年平均时间损失,并通过将时间损失乘以平均每小时工资来计算相关成本。我们按服务类型(住院、门诊和处方药)计算了 T2D 的总直接医疗费用和 T2D 的直接医疗费用。我们使用两部分模型(生产力损失和成本以及住院和药物成本)和广义线性模型(总门诊成本)对按年龄和性别进行的总体和亚组分析。所有成本均以 2019 年美元计算。

结果

患有 T2D 的员工比没有糖尿病的员工缺勤多出 4.2 天(20.8 天与 20.3 天缺勤,6.4 天与 3.3 天 STD 缺勤,1.0 天与 0.4 天 LTD 缺勤)。生产力成本高出 13.3%(680 美元),医疗费用翻了一番(总费用为 11354 美元与 5101 美元;门诊费用为 4558 美元与 2687 美元,住院费用为 3085 美元与 1349 美元,处方药费用为 4182 美元与 1189 美元)。18-34 岁的员工 STD 缺勤和门诊费用更高。女性的缺勤和 STD 缺勤天数以及门诊费用均高于男性。

结论

T2D 导致每年人均成本增加近 7000 美元,主要是由于医疗费用增加。我们的估计可能有助于雇主评估从帮助员工预防或更好地管理 T2D 的努力中获得潜在经济收益的能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ff/9633402/7a25655c8611/nihms-1840685-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ff/9633402/40b458025b88/nihms-1840685-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ff/9633402/7a25655c8611/nihms-1840685-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ff/9633402/40b458025b88/nihms-1840685-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37ff/9633402/7a25655c8611/nihms-1840685-f0002.jpg

相似文献

1
Productivity Loss and Medical Costs Associated With Type 2 Diabetes Among Employees Aged 18-64 Years With Large Employer-Sponsored Insurance.18-64 岁有大型雇主赞助保险的员工中 2 型糖尿病导致的生产力损失和医疗费用。
Diabetes Care. 2022 Nov 1;45(11):2553-2560. doi: 10.2337/dc22-0445.
2
Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.美国胆管癌患者的生产力损失结果及成本:一项经济学评估
J Med Econ. 2023 Jan-Dec;26(1):454-462. doi: 10.1080/13696998.2023.2187604.
3
Impact of COVID-19 on work loss in the United States- A retrospective database analysis.2019冠状病毒病对美国工作损失的影响——一项回顾性数据库分析
J Med Econ. 2024 Jan-Dec;27(1):941-951. doi: 10.1080/13696998.2024.2379056. Epub 2024 Jul 18.
4
Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States.美国 1 型糖尿病成人患者年度医疗保健费用估算。
J Manag Care Spec Pharm. 2020 Mar;26(3):311-318. doi: 10.18553/jmcp.2020.26.3.311.
5
Economic costs of diabetes in the US in 2002.2002年美国糖尿病的经济成本。
Diabetes Care. 2003 Mar;26(3):917-32. doi: 10.2337/diacare.26.3.917.
6
Medical Costs, Health Care Utilization, and Productivity Losses Associated with Hypertension Moderated by COVID-19 Diagnosis Among US Commercial Enrollees.美国商业保险参保人群中,与高血压相关的医疗费用、医疗保健利用率及生产力损失受新冠病毒诊断的影响情况。
Am J Hypertens. 2025 May 13. doi: 10.1093/ajh/hpaf081.
7
The association between employee obesity and employer costs: evidence from a panel of U.S. employers.员工肥胖与雇主成本之间的关联:来自美国雇主样本的证据。
Am J Health Promot. 2014 May-Jun;28(5):277-85. doi: 10.4278/ajhp.120905-QUAN-428.
8
Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.经济负担与腹泻型肠易激综合征:美国商业保险人群的回顾性分析。
J Manag Care Spec Pharm. 2017 Apr;23(4):453-460. doi: 10.18553/jmcp.2016.16138. Epub 2016 Nov 21.
9
Four-year review of presenteeism data among employees of a large United States health care system: a retrospective prevalence study.美国大型医疗保健系统员工出勤主义数据四年回顾:一项回顾性患病率研究。
Hum Resour Health. 2018 Nov 9;16(1):59. doi: 10.1186/s12960-018-0321-9.
10
Specialty drug and health care utilization vary by wage level in employer-sponsored health plans.雇主赞助的健康计划中,特种药物和医疗保健的使用因工资水平而异。
J Manag Care Spec Pharm. 2022 Aug;28(8):918-928. doi: 10.18553/jmcp.2022.22091. Epub 2022 Jun 18.

引用本文的文献

1
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.替尔泊肽和司美格鲁肽对美国成年人的终生健康影响及成本效益
JAMA Health Forum. 2025 Mar 7;6(3):e245586. doi: 10.1001/jamahealthforum.2024.5586.
2
Clinical Outcome and Costs Based on the Degree of Vitamin K Antagonist Control for Non-Valvular Atrial Fibrillation.基于非瓣膜性心房颤动维生素K拮抗剂控制程度的临床结局和成本
J Clin Med. 2025 Feb 4;14(3):998. doi: 10.3390/jcm14030998.
3
Challenges and support factors in managing type 2 diabetes among pregnant women in Thailand: A convergent mixed-methods study.

本文引用的文献

1
Comprehensive cost-effectiveness of diabetes management for the underserved in the United States: A systematic review.美国服务不足人群的糖尿病管理综合成本效益:系统评价。
PLoS One. 2021 Nov 18;16(11):e0260139. doi: 10.1371/journal.pone.0260139. eCollection 2021.
2
Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review.针对高危个体和整个人群的糖尿病预防干预措施的成本效益:系统评价。
Diabetes Care. 2020 Jul;43(7):1593-1616. doi: 10.2337/dci20-0018.
3
Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States.
泰国孕妇管理2型糖尿病的挑战与支持因素:一项聚合性混合方法研究。
Belitung Nurs J. 2025 Jan 26;11(1):35-47. doi: 10.33546/bnj.3639. eCollection 2025.
4
Health and Oral Health-Related Quality of Life and the Associated Factors in Diabetic Patients.糖尿病患者的健康及与口腔健康相关的生活质量及其相关因素
Cureus. 2024 Dec 7;16(12):e75269. doi: 10.7759/cureus.75269. eCollection 2024 Dec.
5
Antihypertensive Medication Adherence and Medical Costs, Health Care Use, and Labor Productivity Among People With Hypertension.高血压患者的降压药物依从性与医疗费用、医疗保健利用和劳动生产力。
J Am Heart Assoc. 2024 Nov 5;13(21):e037357. doi: 10.1161/JAHA.124.037357. Epub 2024 Nov 4.
6
Health and Productivity Benefits with Early Intensified Treatment in Patients with Type 2 Diabetes: Results from Korea.韩国:2 型糖尿病患者早期强化治疗的健康和生产力获益结果。
Inquiry. 2024 Jan-Dec;61:469580241240106. doi: 10.1177/00469580241240106.
评估美国接受 GINA 4/5 治疗的哮喘患者的直接成本和生产力损失。
Ann Allergy Asthma Immunol. 2019 Dec;123(6):564-572.e3. doi: 10.1016/j.anai.2019.08.462. Epub 2019 Sep 6.
4
Trajectory of Excess Medical Expenditures 10 Years Before and After Diabetes Diagnosis Among U.S. Adults Aged 25-64 Years, 2001-2013.25-64 岁美国成年人糖尿病诊断前 10 年和后 10 年的过度医疗支出轨迹,2001-2013 年。
Diabetes Care. 2019 Jan;42(1):62-68. doi: 10.2337/dc17-2683. Epub 2018 Nov 19.
5
Economic Costs of Diabetes in the U.S. in 2017.2017 年美国糖尿病的经济成本。
Diabetes Care. 2018 May;41(5):917-928. doi: 10.2337/dci18-0007. Epub 2018 Mar 22.
6
Modeling Health Care Expenditures and Use.建模医疗保健支出和使用。
Annu Rev Public Health. 2018 Apr 1;39:489-505. doi: 10.1146/annurev-publhealth-040617-013517. Epub 2018 Jan 12.
7
Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data.基于电子健康记录数据的成人 1 型糖尿病识别算法的验证。
Pharmacoepidemiol Drug Saf. 2018 Oct;27(10):1053-1059. doi: 10.1002/pds.4377. Epub 2018 Jan 2.
8
A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC's National Diabetes Prevention Program.全国努力预防 2 型糖尿病:美国疾病控制与预防中心国家糖尿病预防计划的参与者水平评估。
Diabetes Care. 2017 Oct;40(10):1331-1341. doi: 10.2337/dc16-2099. Epub 2017 May 12.
9
Absenteeism and Employer Costs Associated With Chronic Diseases and Health Risk Factors in the US Workforce.美国劳动力中与慢性病和健康风险因素相关的旷工现象及雇主成本。
Prev Chronic Dis. 2016 Oct 6;13:E141. doi: 10.5888/pcd13.150503.
10
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus.2型糖尿病风险、病理生理学及并发症中的性别差异
Endocr Rev. 2016 Jun;37(3):278-316. doi: 10.1210/er.2015-1137. Epub 2016 May 9.